News Beyond Our Pages

Benralizumab is a humanized mAb that depletes cells expressing the IL-5 receptor α subunit, including eosinophils, and reduces the frequency of asthma exacerbations. Nair et al (N Engl J Med 2017;376:2448-58; http://ift.tt/2xLyiNw) performed a randomized double-blind trial to determine the oral glucocorticoid–sparing potential of benralizumab in patients with severe asthma controlled with oral glucocorticoids in addition to inhaled corticosteroids and long-acting bronchodilators and evidence of an "eosinophil phenotype" demonstrated by blood eosinophilia.

http://ift.tt/2x8ghfr